Among the top losers from sugar sector were Shree Renuka Sugars which plunged over 7% in the opening trade amid high volumes, followed by Balrampur Chini, Rana Sugar, The Ugar Sugar Works and Dwarikesh Sugar, which lost up to 3%.
Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800. The company is set for strong growth over the next 3 years. The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).
Power is a multi-year story. The power stocks have just started reacting. There can be a very sharp run from here also. Although we do not have any formal coverage, I am again highlighting that this space itself is becoming very attractive. So, the power story can be interesting.